<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04040023</url>
  </required_header>
  <id_info>
    <org_study_id>2019-A01522-55</org_study_id>
    <nct_id>NCT04040023</nct_id>
  </id_info>
  <brief_title>Patient Blood Management in Cardiac Surgery</brief_title>
  <acronym>PBMc</acronym>
  <official_title>Optimization of Transfusion Use and Interest of the Correction of Iron Deficiencies in Cardiac Surgery Under Extracorporeal Circulation (ECC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinique Pasteur</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clinique Pasteur</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Preoperative anemia is associated with an important increase in transfusions of red blood
      cells (RBC) compared to a non-anemic patient in cardiac and non cardiac surgery. Furthermore
      transfusion is also an independent factor of morbi-mortality with notably an increase in the
      infectious risk, immunological, an increase of the risk of cardiac decompensation,
      respiratory decompensation Transfusion Related Acute Lung Injury (TRALI) or Transfusion
      Associated Cardiac Overload (TACO), and an increase in mortality of 16%.

      Management of perioperative transfusion is therefore a public health issue. Since 2010, the
      World Health Organization (WHO) has been promoting a systematic approach to implement blood
      management programs for the patient to optimize the use of resources and promote quality and
      safety of care.

      Improving the relevance of transfusion in cardiac surgery could be achieved by optimizing the
      management of patients around 2 axis:

      A:non-drug intervention : Review of Practices to Improve the Management of Perioperative RBC
      Transfusion

      B:drug intervention : Systematic correction of pre- and postoperative iron, vitamin
      deficiencies and anemia

      The aim of this program is to improve the relevance of transfusion in cardiac surgery and to
      limit the morbidity and mortality induced by transfusion. This program is part of a global
      project of pre, per and postoperative management of the patient undergoing cardiac surgery
      programmed under extracorporeal circulation (ECC). It requires a multidisciplinary approach
      between cardiologists, anesthesiologists and intensivists, perfusionists, cardiac surgeons
      and paramedical teams to optimize the management of the patient.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 10, 2019</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Prospective monocentric superiority study in two successive steps</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>RBC transfusion rate</measure>
    <time_frame>Between surgery and hospital discharge, an average of 10 days</time_frame>
    <description>Proportion of patient who received at least one RBC transfusion during their hospitalization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>between baseline (1 month before surgery) and 3 months after surgery</time_frame>
    <description>Occurrence of adverse event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transfusion parameters</measure>
    <time_frame>between surgery and hospital discharge, an average of 10 days</time_frame>
    <description>Transfusion rate, use of poly transfusion, hemodilution, transfusion thresholds and postoperative bleeding volume.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood test parameters</measure>
    <time_frame>between baseline (1 month before surgery) and 3 months after surgery</time_frame>
    <description>hemoglobin, ferritin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6 min walk test</measure>
    <time_frame>at discharge of the healthcare and rehabilitation units</time_frame>
    <description>Walking test : distance reach after 6 min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New York Heart Association (NYHA)</measure>
    <time_frame>between baseline (1 month before surgery) and 3 months after surgery</time_frame>
    <description>NYHA Functional Classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Euro Quality of life 5 dimensions (EQ5D)</measure>
    <time_frame>between baseline (1 month before surgery) and 3 months after surgery</time_frame>
    <description>EQ5D Quality of life questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">900</enrollment>
  <condition>Surgical Blood Loss</condition>
  <arm_group>
    <arm_group_label>I Group: PBMi</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Non-drug intervention First part of PBM program (PBMi) Training part for medical care staff to improve transfusion practices</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C Group: PBMc</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient Blood Management: full program
PBMi intervention and Drug intervention (systematic correction of pre- and postoperative iron and vitamin deficiencies, and erythropoietin preoperative treatment for anemic patient)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iron and vitamin Deficiencies Correction Program</intervention_name>
    <description>Preoperative:
For patient with iron deficiency: Intravenous iron supplementation For patient with folic acid or vitamin B12 deficiency : oral vitamin supplementation For patient with anemia: pre operative erythropoietin injections
Postoperative:
Systematic iron supplementation</description>
    <arm_group_label>C Group: PBMc</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PBMi: Training program to improve transfusion practices</intervention_name>
    <description>Training program to sensitize health care staff to streamline the use of transfusion targeting the following points: limit perioperative and post operative hemodilution; to adapt the transfusion threshold to the tolerance of the patient to anemia in per and postoperative; justify the use of RBC transfusion by setting up a questionnaire; encourage transfusion of RBC unit by unit.</description>
    <arm_group_label>C Group: PBMc</arm_group_label>
    <arm_group_label>I Group: PBMi</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient scheduled for cardiac surgery under ECC

          -  Patient affiliated or beneficiary of a social security scheme

          -  Patient having given his consent

        Exclusion Criteria:

          -  Urgent surgery (less than 48h)

          -  Contraindication to iron injection : proven allergic reaction

          -  Erythropoietin allergy

          -  Protected patients: Majors under some form of guardianship or other legal protection;
             pregnant, breastfeeding or parturient woman.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hélène Charbonneau, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinique Pasteur</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hélène Charbonneau, MD, PhD</last_name>
    <phone>+33 5 62 21 16 83</phone>
    <email>hcharbonneau@clinique-pasteur.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Toulouse cedex 3</city>
        <zip>31076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hélène Charbonneau, MD, PhD</last_name>
      <phone>+33 5 62 21 16 83</phone>
      <email>hcharbonneau@clinique-pasteur.com</email>
    </contact>
    <investigator>
      <last_name>Hélène Charbonneau, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicolas Mayeur, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivier Anglès, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gérard Autones, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne-Laure Berthelot, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isabelle Decramer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Duterque, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yannick Gabiache, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Valérie Julien, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laurent Mallet, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mimoun M'Rini, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-François Quedreux, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benoît Richard, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laurent Sidobre, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laurence Taillefer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Madeleine Croute-Bayle, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>July 25, 2019</study_first_submitted>
  <study_first_submitted_qc>July 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2019</study_first_posted>
  <last_update_submitted>February 13, 2020</last_update_submitted>
  <last_update_submitted_qc>February 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Clinique Pasteur</investigator_affiliation>
    <investigator_full_name>Dr Hélène Charbonneau</investigator_full_name>
    <investigator_title>Principal investigator, MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Red Blood Cell transfusion</keyword>
  <keyword>Anemia</keyword>
  <keyword>Iron deficiency</keyword>
  <keyword>Extracorporeal circulation or Bypass</keyword>
  <keyword>Cardiac Surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Blood Loss, Surgical</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

